Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03806569
Other study ID # KUCHLER_2018
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2019
Est. completion date December 2022

Study information

Verified date August 2021
Source Neuropsychiatrischen Zentrums Hamburg-Altona
Contact Peter Tonn, Dr. med.
Phone +494053307380
Email tonn@npz-hamburg.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is developed to validate a new short psychotherapeutic group treatment for adults with ADHD diagnosis. The participants will be treated in a monocentric, parallel group randomized superiority study - one group with the new treatment and one group with well established relaxing treatment.


Description:

Background: Attention deficit hyperactivity disorder (AD(H)D) symptoms are often assumed to decease in adolescence, however in up to 60% of children, AD(H)D persists into adulthood. Currently, pharmacological therapy is the number-one choice AD(H)D treatment. Despite its evidenced effects of pharmacological interventions there are side effects, contraindications and non-responders, which send some patients disliking the use of medication and asking for alternative treatments. In previous studies mindfulness-based interventions already have shown similar effects in neural regions as pharmacological treatment and positive changes in AD(H)D symptoms, quality of life, awareness and concentration. The following study wants to improve mindfulness-based treatment approaches in AD(H)D with a new therapy concept. Methods: Mindfulness, acceptance, commitment and cognitive behavioral group therapy (MAC-CBT) combines 3rd wave therapies with focus on mindfulness meditation, acceptance of unchangeability, commitment to new goals with elements of cognitive behavioral therapy. The design of this study is a single-center, parallel-group, randomized superiority trial. The aim is to compare MAC-CBT group with progressive muscle relaxation training (PMR by Jacobson). Both groups will be held over a period of eight weeks. Participants will be assessed two times before treatment to determine natural course of adult AD(H)D and two times after treatment to evaluate short and long term effects. A questionnaire battery and neuropsychological tests are to be used to obtain results regarding a possible change in the symptoms and attention, including selective attention. Discussion: This trial will offer new knowledge about the effects of third wave therapies on AD(H)D. Furthermore, the following study is one of few studies that will compare AD(H)D treatment to relaxation training instead of comparison to waiting list. The aim of the following study is to verify previous outcomes of mindfulness-based treatments on AD(H)D and to evaluate superiority of mindfulness towards relaxation programs.


Recruitment information / eligibility

Status Recruiting
Enrollment 180
Est. completion date December 2022
Est. primary completion date April 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - adult ADHD - written informed consent - stable medication for at least two weeks - sufficient knowledge of the German language Exclusion Criteria: - personality disorder - schizophrenia / psychotic disorders - bipolar disorder - acute suicidality - disease of the central nervous system - no other psychotherapeutic treatment at the time of the study - pregnancy - IQ below 70 Points

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
MAC-cbt group treatment for adult ADHD
Psychotherapeutic intervention to treat adult patients with ADHD to be mindful, accept the symptoms and disturbances and commit with the situation or the possibility to change.
Jacobson
Relaxation treatment in technique of Jacobson in 8 sessions

Locations

Country Name City State
Germany Neuropsychiatric Center of Hamburg Hamburg

Sponsors (2)

Lead Sponsor Collaborator
Peter Tonn Universitätsklinikum Hamburg-Eppendorf

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of Symptoms measured by the Connors ADHD Adult Rating Scale (CAARS) The long version of the CAARS (Conner's Adult AD(H)D Rating Scales (Christiansen et al., 2012)) combines self-report and observer rating questionnaires to assess current AD(H)D symptoms in adulthood. This instrument consists of 66 items based on a 4-point Likert scale and four subscales: Inattention/ Memory Problems, Hyperactivity/ Restlessness, Impulsivity/ Emotional Lability and Problems with Self-Concept. With regard to the scientific quality criteria, Christiansen (2012) reports internal consistencies with a Cronbach's a of .74 to .95 and a test-retest reliability from .71 to .93, range min. 66 to max. 264 points. Measurement 1 at inclusion date, Measurement 2 two months later measurement 1, then measurement 3 immediately after intervention, measurement 4 as catamnestic follow up 6 months after intervention
Secondary Measure of the quality of life of the participants measured by World Health Organization Quality of Life Questionnaire Quality of life will be assessed by the short version of WHOQOL-BREF (World Health Organization Quality of Life Questionnaire (Group, 1998)). The questionnaire consists of 26 items that were extracted from the complete version consists of 100 items (WHOQOL-100) based on a 5-point Likert scale. For the German short version, Cronbach's alpha scores between .76 and .88 (Skevington, Lotfy, O'Connell, & Group, 2004). Range from 26 to 105 (min.-max). Measurement 1 at inclusion date, Measurement 2 two months later measurement 1, then measurement 3 immediately after intervention, measurement 4 as catamnestic follow up 6 months after intervention
Secondary Changes of attention functioning measured by change detection task and trail making test A and B of the computer based test setting Psychology Experiment Building Language (PEBL) The change detection task, modeled paradigm by Luck and Vogel, examines the visual working memory and covers sustained and selective attention. Patients will see a first pattern of differently colored squares for 300ms followed by a 1000ms pause and then a second pattern of squares. The task is then to determine whether the colors of every square are identical, will be repeated 120 times and takes approximately 12 minutes in total. Reaction times and the amount of mistakes made will then give information on the level of functioning. In addition, a TMT-A and B (Reitan, 1992) will be conducted. Patients will be asked to first connect numbers ranging from 1 to 30 in increasing order and then numbers from one to 15 and letters from A through O alphabetically alternating. Reaction times, times between clicks and the amount of correct and incorrect clicks will provide insight to the level of attentional functioning. Measurement of single individual scores, no qualified range described. Measurement 1 at inclusion , Measurement 2 is 2 months after inclusion, measurement 3 immediately after intervention, measurement 4 as catamnestic follow up 6 months after intervention
Secondary Changes of mindfulness measured by Mindful Attention Awareness Scale In order to assess mindfulness as well as the perception of the "here and now", the German version of the MAAS (Mindful Attention Awareness Scale (Brown & Ryan, 2003)) is used. In total, it consists of 15 items on a 6-point Likert scale. Since non-mindful behaviors are described, high scores mean a higher level of mindfulness. The internal consistency, represented by Cronbach's alpha, amounts a = .83 for the German version (Michalak, Heidenreich, Ströhle, & Nachtigall, 2008).Range form 15 to 90 points. Measurement 1 at inclusion date, Measurement 2 two months later measurement 1, then measurement 3 immediately after intervention, measurement 4 as catamnestic follow up 6 months after intervention
Secondary Changes of acceptance, measured by Acceptance and Action Questionnaire The FAH II Questionnaire (Acceptance and Action Questionnaire), the German version of AAQ (Acceptance and Action Questionnaire (Bond et al., 2011; Hoyer & Gloster, 2013)), aims to measure acceptance and psychological flexibility. The questionnaire consists of seven items, based on a 7-point Likert scale. Hoyer and Gloster found Cronbach's alpha between.84 and .97 and a test-retest reliability of rtt = .74 - .85 for the German version (2011). Range from 7 to 49 points. Measurement 1 at inclusion date, Measurement 2 two months later measurement 1, then measurement 3 immediately after intervention, measurement 4 as catamnestic follow up 6 months after intervention
Secondary Affective state measured with the Patient Health Questionnaire PHQ-9 The PHQ (Patient Health Questionnaire, (Gräfe, Zipfel, Herzog, & Löwe, 2004)) is used for psychodiagnostic screening and a possible change in patient depression. It is a self-assessment tool based on the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV (Saß & Association, 1998)) and includes modules on somatoform disorders, depressive disorders, anxiety disorders, and eating disorders, alcohol abuse, psychosocial functioning, stressors, critical life events and for participants to menstruation, pregnancy and childbirth. In total, it contains 78 items, which are based on a 2- to 5-point Likert scale depending on the module. For the depression scale of PHQ-D the internal consistency according to Cronbach's alpha is a = .88, for the somatization scale a = .79. Different subscales, no combined score, individual ranges and scores. Measurement 1 at inclusion date, Measurement 2 two months later measurement 1, then measurement 3 immediately after intervention, measurement 4 as catamnestic follow up 6 months after intervention
Secondary Measuring of satisfaction and willingness to change with visual analogue scales Visual analogue scales (VAS) with regard to satisfaction with mental health and the willingness to change are going to be evaluated.Range from 0 to 10 per scale, no combined scores. Measurement 1 at inclusion date, Measurement 2 two months later measurement 1, then measurement 3 immediately after intervention, measurement 4 as catamnestic follow up 6 months after intervention
Secondary Measuring of five individual parameters during every of the single treatment session Each time before and after the therapy sessions, five visual analogue scales are to be filled in, on which patients evaluate their current mood, stress, restlessness, trust in effectiveness of psychotherapy and their energy level. Range from 0 to 10 per scale, no combined scores. Measurement before and after every treatment session, 2-6 weeks after inclusion date, every week for the 8 weeks treatment period
See also
  Status Clinical Trial Phase
Recruiting NCT04356924 - Psychological Treatment to Support the Consequences of Cognitive Impairment N/A
Recruiting NCT05030285 - Telehealth Psychotherapy for Anxiety in Persons With Cognitive Impairment N/A
Not yet recruiting NCT05863637 - Intensive Short-Term Dynamic Psychotherapy (ISTDP) for Anxiety Diagnoses in a Primary Care Setting N/A
Active, not recruiting NCT05018312 - Modified Collaborative Assessment VS Standard Assessment on Readiness For Psychotherapy Among Patients With Anxiety N/A
Not yet recruiting NCT06038747 - Self-monitoring and Reflection's Impact on Psychotherapy Outcomes: A Trial Protocol. N/A
Not yet recruiting NCT00808600 - Empowerment of Lung and Heart-lung Transplant Patients N/A
Not yet recruiting NCT03706001 - Efficacy of Psychotherapy for Improving Quality of Life in Patients With Hypertrophic Cardiomyopathy and Depression N/A
Recruiting NCT05587517 - A Clinical Trial of Interventions to Support Family Surrogates of Critically Ill Patients Phase 2
Completed NCT05385458 - Acceptance and Commitment Therapy (ACT) Tele-Counselling N/A
Not yet recruiting NCT06366685 - Development and Initial Application of a Combined Exercise and Psychological Intervention Program for Patients After Esophagectomy N/A
Active, not recruiting NCT04950608 - Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care Phase 2
Not yet recruiting NCT05613972 - Brief Suicide & Trauma Therapy for Suicide Risk N/A
Active, not recruiting NCT03692130 - Treatment of Depression With Mindfulness, Acceptance and Commitment N/A
Recruiting NCT05356611 - Engage for Late-Life Depression and Comorbid Executive Dysfunction N/A
Not yet recruiting NCT06347822 - Increasing Access to Evidence-Based Care in Integrated Behavioral Health N/A
Not yet recruiting NCT05317598 - The Key Model Of Courtesy And Integrıty N/A
Not yet recruiting NCT06353282 - MDMA-Assisted Psychotherapy for Treatment Resistant PTSD in Adolescents Phase 2
Not yet recruiting NCT03813264 - Optimizing Outcomes of Dynamic Psychotherapy by the MATRIX: A Preliminary Study N/A
Completed NCT05289583 - Impact of Therapeutic Alliance on Dropout in a Naturalistic Sample of Patients With Borderline Pathology Receiving Residential DBT
Completed NCT03937167 - Benefits of Group Psychotherapy Programs in the Treatment of Obesity N/A